Based on our previous studies suggesting a possible inverse relationship between MTA1 and PTEN [9, 17], we hypothesized that MTA1-targeted therapy would be effective for blocking Pten loss-driven prostate tumor growth and progression. Here, PTEN is linked to prostate neoplasm.